What does TRIMEPHAR do?

TRIMEPHAR is a pharmacy in Faimes. Private Limited, started on 20 October 2008, 1 establishment.

What is the address of TRIMEPHAR?

The registered office of TRIMEPHAR is located at Rue de la Champignotte(AIN) 13, 4317 Faimes.

Is TRIMEPHAR still active?

Yes. According to the CBE (29 October 2026) TRIMEPHAR is active, legal situation “Normale toestand”, started on 20 October 2008.

Is TRIMEPHAR registered on Peppol?

Yes, TRIMEPHAR is registered on the Peppol network with ID 0208:0807210244.

What is the enterprise number of TRIMEPHAR?

The enterprise number of TRIMEPHAR is BE0807210244.

When was TRIMEPHAR founded?

TRIMEPHAR was founded on 20 October 2008.

Who are the directors of TRIMEPHAR?

According to the 2025 annual accounts, the directors of TRIMEPHAR are: PHARMACIE LEJEUNE SA.

Is TRIMEPHAR a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 20 October 2008; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did TRIMEPHAR make in 2025?

TRIMEPHAR posted a profit after taxes of € 166,856 in financial year 2025.

What is the revenue of TRIMEPHAR?

As a small company, TRIMEPHAR is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 528,584.

How much does an employee at TRIMEPHAR earn?

The average wage cost per full-time employee at TRIMEPHAR was € 65,500 in 2025: staff costs of € 235,623 for 3.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does TRIMEPHAR have?

According to the 2025 annual accounts, TRIMEPHAR has 3.6 full-time equivalents (FTE).

TRIMEPHAR (Private Limited) - Faimes - BE0807210244

Dossier TRIMEPHAR, printed on 29 October 2026 from databakkes.be/en/0807210244/trimephar. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 62 % of short-term debt in 2025; threshold 65 %.
Busy address KBO

16 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

TRIMEPHAR from Faimes, company number BE0807210244, closed financial year 2025 with a result of € 166,856 after tax. For that financial year TRIMEPHAR recorded a gross margin of € 528,584 and equity of € 777,347. Compared with financial year 2024, the result moved from € 192,134 to € 166,856. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.

What it is worth Healthy

€ 777,347

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 166,856

▼ 13% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 188,060

▲ 29% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 170,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

3.6

▼ 0.6 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 235,623

▲ 2% vs 2024

€ 65,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 544

▼ 22% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 5,378

▼ 80% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 125,432

▼ 5% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 37,657

▼ 7% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 558,663 Gross margin 2022: € 558,663 First fiscal year in the series	€ 557,871 Gross margin 2023: € 557,871 Unchanged (€ 558,663) Unfavourable step	€ 557,512 Gross margin 2024: € 557,512 Unchanged (€ 557,871) Unfavourable step	€ 528,584 Gross margin 2025: € 528,584 ▼ 5% vs 2024 (€ 557,512) Unfavourable step	▼ 5%
Profit after taxes	€ 191,442 Profit after taxes 2022: € 191,442 First fiscal year in the series	€ 183,579 Profit after taxes 2023: € 183,579 ▼ 4% vs 2022 (€ 191,442) Unfavourable step	€ 192,134 Profit after taxes 2024: € 192,134 ▲ 5% vs 2023 (€ 183,579) Favourable step	€ 166,856 Profit after taxes 2025: € 166,856 ▼ 13% vs 2024 (€ 192,134) Unfavourable step	▼ 13%
Equity	€ 764,778 Equity 2022: € 764,778 First fiscal year in the series	€ 768,357 Equity 2023: € 768,357 Unchanged (€ 764,778) Favourable step	€ 780,491 Equity 2024: € 780,491 ▲ 2% vs 2023 (€ 768,357) Favourable step	€ 777,347 Equity 2025: € 777,347 Unchanged (€ 780,491) Unfavourable step
Total debts	€ 616,557 Total debts 2022: € 616,557 First fiscal year in the series	€ 648,191 Total debts 2023: € 648,191 ▲ 5% vs 2022 (€ 616,557) Unfavourable step	€ 509,117 Total debts 2024: € 509,117 ▼ 21% vs 2023 (€ 648,191) Favourable step	€ 518,968 Total debts 2025: € 518,968 ▲ 2% vs 2024 (€ 509,117) Unfavourable step	▲ 2%
Cash	€ 124,998 Cash 2022: € 124,998 First fiscal year in the series	€ 195,463 Cash 2023: € 195,463 ▲ 56% vs 2022 (€ 124,998) Favourable step	€ 145,789 Cash 2024: € 145,789 ▼ 25% vs 2023 (€ 195,463) Unfavourable step	€ 188,060 Cash 2025: € 188,060 ▲ 29% vs 2024 (€ 145,789) Favourable step	▲ 29%
Land & buildings	€ 901,314 Land & buildings 2022: € 901,314 First fiscal year in the series	€ 840,056 Land & buildings 2023: € 840,056 ▼ 7% vs 2022 (€ 901,314) Unchanged	€ 778,799 Land & buildings 2024: € 778,799 ▼ 7% vs 2023 (€ 840,056) Unchanged	€ 717,542 Land & buildings 2025: € 717,542 ▼ 8% vs 2024 (€ 778,799) Unchanged	▼ 8%
Retained profit	€ 664,778 Retained profit 2022: € 664,778 First fiscal year in the series	€ 668,357 Retained profit 2023: € 668,357 ▲ 1% vs 2022 (€ 664,778) Favourable step	€ 680,491 Retained profit 2024: € 680,491 ▲ 2% vs 2023 (€ 668,357) Favourable step	€ 677,347 Retained profit 2025: € 677,347 Unchanged (€ 680,491) Unfavourable step
Dividend	€ 180,000 Dividend 2022: € 180,000 First fiscal year in the series	€ 180,000 Dividend 2023: € 180,000 Unchanged (€ 180,000) Unchanged	€ 180,000 Dividend 2024: € 180,000 Unchanged (€ 180,000) Unchanged	€ 170,000 Dividend 2025: € 170,000 ▼ 6% vs 2024 (€ 180,000) Unchanged	▼ 6%
Bank debt	€ 66,838 Bank debt 2022: € 66,838 First fiscal year in the series	€ 46,968 Bank debt 2023: € 46,968 ▼ 30% vs 2022 (€ 66,838) Favourable step	€ 26,488 Bank debt 2024: € 26,488 ▼ 44% vs 2023 (€ 46,968) Favourable step	€ 5,378 Bank debt 2025: € 5,378 ▼ 80% vs 2024 (€ 26,488) Favourable step	▼ 80%
Balance sheet total	€ 1,381,335 Balance sheet total 2022: € 1,381,335 First fiscal year in the series	€ 1,416,548 Balance sheet total 2023: € 1,416,548 ▲ 3% vs 2022 (€ 1,381,335) Unchanged	€ 1,289,608 Balance sheet total 2024: € 1,289,608 ▼ 9% vs 2023 (€ 1,416,548) Unchanged	€ 1,296,315 Balance sheet total 2025: € 1,296,315 ▲ 1% vs 2024 (€ 1,289,608) Unchanged	▲ 1%
Employees (FTE)	4.3 Employees (FTE) 2022: 4.3 First fiscal year in the series	4.2 Employees (FTE) 2023: 4.2 ▼ 0.1 vs 2022 (4.3) Unchanged	4.2 Employees (FTE) 2024: 4.2 Unchanged (4.2) Unchanged	3.6 Employees (FTE) 2025: 3.6 ▼ 0.6 vs 2024 (4.2) Unchanged	▼ 0.6

Key figures of TRIMEPHAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to TRIMEPHAR?

What happened at TRIMEPHAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 17, 2026 New annual accounts for financial year 2025: profit of € 166,856 (▼ 13% vs 2024). Source: NBB ↗
Jan 1, 2009 New establishment in Mettet. KBO
Oct 20, 2008 Start of the company according to the CBE. KBO

In short

From € 191,442 profit in 2022 to € 166,856 profit in 2025.

Paid € 247,778 in corporate taxes since 2022.

Best year ever: 2024, with € 192,134 profit.

On average € 146,800 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

PHARMACIE LEJEUNE 100%

The stake of PHARMACIE LEJEUNE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

TRIMEPHAR

Behind TRIMEPHAR is PHARMACIE LEJEUNE SA. The shares are held by PHARMACIE LEJEUNE (100%).

Directors

According to the 2025 annual accounts

PHARMACIE LEJEUNE SA

Director · represented by François-Xavier OLIVIER

Also active at: PHARMACIE BEAUMONT, Pharmacie J.P. Detry - Discry, PHARMACIE DES FORGES, PHARMACIE DE DONCEEL, PHARMACIE DUBOIS-HUSSON, Pharmacie DETRY-DUPONT, PHARMACIE R. WALNIER, Pharmacie BILLEN +10 more

Shareholders

PHARMACIE LEJEUNE

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de la Champignotte(AIN) 13

4317 Faimes

2.175.726.133

Rue Albert Ier 119

5640 Mettet

Active since 1 January 2009

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 16 companies are registered at this address.

All companies at this address →

Pharmacie J.P. Detry - Discry same network

€ 255,389 gross margin · 2025

PHARMACIE DE DONCEEL same network

€ 175,420 gross margin · 2025

PHARMACIE DUBOIS-HUSSON same network

€ 475,076 gross margin · 2025

Pharmacie DETRY-DUPONT same network

€ 297,327 gross margin · 2025

PHARMACIE R. WALNIER same network

€ 463,240 gross margin · 2025

+11 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0807.210.244

VAT number

BE 0807.210.244

Registered office

Rue de la Champignotte(AIN) 13, 4317 Faimes

Names & denominations

TRIMEPHAR

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

20 October 2008

Peppol

Active · Active since 10 Sept 2025

Activities · NACE

Detailhandel in farmaceutische producten

Detailhandel in cosmetica en toiletartikelen

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

TRIMEPHAR

Warning lights

Financials

What happened to TRIMEPHAR?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions